Research Site

Alabaster, Alabama 35007

1 studies enrolling now · 8 studies all time

What they study most

APOL1-Mediated Kidney Disease, Breast Cancer, Carcinoma, Erosive Esophagitis, GERD, GERD With Erosive Esophagitis, GERD Without Erosive Esophagitis, Gastroesophageal Reflux Disease, IgAN, Immunoglobulin A Nephropathy, Metastases, Neoplasm

Studies at this site

• Dose-Ranging Safety, Tolerability, and Efficacy Study of AZD2373 in Participants With APOL1-Mediated Kidney Disease — Recruiting now
• Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN) — Running, not enrolling
• Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding — Completed
• Iressa Expanded Access Program (EAP) — Completed
• A Dose-finding Phase IIb Study With AZD0865 and Esomeprazole in GERD Patients With Erosive Esophagitis. — Completed
• A Dose-finding Phase IIb Study With AZD0865 and Esomeprazole in GERD Patients Without Erosive Esophagitis. — Completed
• NEXIUM® in the Treatment of Moderate and Severe Erosive Esophagitis — Completed
• An Open-Label Study of Once-Daily Oral Administration of Esomeprazole 40 mg in Patients With Symptoms of Gastroesophageal Reflux Disease (GERD) — Completed